Ancient herbal mix may shorten hospital stays for COPD patients
NCT ID NCT07403032
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether adding a modified Chinese herbal decoction (Ma Xing Shi Gan) to standard care helps people with COPD flare-ups recover faster. Two hundred participants will be randomly assigned to receive either standard care alone or standard care plus the herbal formula for 14 days. The main goal is to see if the herbal treatment shortens hospital stays, with additional measures for symptom relief and breathing ability.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- modified Ma Xing Shi Gan Decoction (a Chinese herbal formula)
- What this could lead to
- If it works, this could provide a safe, add-on herbal treatment to help people recover faster from COPD flare-ups and reduce time in the hospital.
- What could go wrong
- This is an early-stage trial with no phase designation, so results are uncertain. The herbal mixture may not work better than standard care alone, and individual responses can vary.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC OBSTRUCTIVE PULMONARY DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Smart breathing machines at home: a new way to predict COPD crises?
- Breathing easy? new X-Ray method may spot COPD decline early
- Could a common heart drug cut COPD hospitalizations?
- Which inhaler breathes better? a Head-to-Head COPD showdown
- Could tiny lung valves revive heart and muscle strength in COPD?
- One lung or two? surgery trial aims to find the best approach for severe COPD